Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Corcept’s New Cancer Pill Boosts Survival for Drug-Resistant Patients

Daniel Kim Views  

Medical Today
Medical Today

Corcept’s innovative cancer treatment has shown promising results in specific ovarian cancer patients who have developed resistance to conventional chemotherapy.

Corcept Therapeutics recently announced that their anticancer drug, Relacorilant, significantly delayed the progression of platinum-resistant ovarian cancer in late-stage clinical trials.

The study involved 381 ovarian cancer patients and revealed that the combination therapy of Relacorilant and chemotherapy reduced the risk of cancer progression by 30% compared to chemotherapy alone. This groundbreaking treatment extended the average survival by 4.5 months, bringing the total to 16 months.

Relacorilant, an oral medication, works by inhibiting cortisol, a stress hormone known to build resistance against chemotherapy treatments such as platinum therapy.

Currently, treatment options for platinum-resistant ovarian cancer are limited, with AbbVie’s Elahere and Roche’s Avastin being the primary choices.

According to the National Cancer Institute, approximately 200,000 women are diagnosed with ovarian cancer in the U.S. annually, with 20,000 of these cases classified as platinum-resistant.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Not Ginseng, But Close: Why Acanthopanax Is the New Wellness Star
  • Neck Wrinkles Giving You Away? Here’s How to Smooth Things Out
  • Real Teeth, Grown in a Lab? Scientists Say It’s Closer Than You Think
  • Truth About Carbs and Kids: Why Balance Is Everything
  • Scabies in the Dorms? Here’s How Fast It Can Spread
  • Drank Last Night? Here's Why Skipping the Gym Might Be Smarter